Anchor Capital Advisors LLC Has $1.06 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Anchor Capital Advisors LLC lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 59.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 14,660 shares of the medical equipment provider’s stock after selling 21,665 shares during the quarter. Anchor Capital Advisors LLC’s holdings in Hologic were worth $1,057,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of HOLX. Swedbank AB lifted its stake in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after buying an additional 306,562 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Hologic by 25.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,114 shares of the medical equipment provider’s stock worth $1,706,000 after acquiring an additional 4,314 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Hologic by 55.1% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the medical equipment provider’s stock worth $607,000 after acquiring an additional 2,645 shares during the period. Integrated Advisors Network LLC increased its position in Hologic by 17.8% during the third quarter. Integrated Advisors Network LLC now owns 5,543 shares of the medical equipment provider’s stock worth $452,000 after acquiring an additional 838 shares during the period. Finally, New York State Teachers Retirement System increased its position in Hologic by 1.7% during the third quarter. New York State Teachers Retirement System now owns 223,157 shares of the medical equipment provider’s stock worth $18,178,000 after acquiring an additional 3,630 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.3 %

HOLX opened at $63.38 on Friday. The company’s 50 day moving average is $69.16 and its 200-day moving average is $75.97. Hologic, Inc. has a 1-year low of $62.69 and a 1-year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $14.22 billion, a P/E ratio of 19.99, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HOLX. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Raymond James reaffirmed an “outperform” rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Finally, Stephens reissued an “overweight” rating and issued a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Ten research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Hologic has an average rating of “Moderate Buy” and an average price target of $85.77.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.